Binding between the integrin alphaXbeta2 (CD11c/CD18) and heparin.

J Biol Chem

Immune Disease Institute (formerly CBR Institute for Biomedical Research), Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA.

Published: October 2007

The interactions between cell surface receptors and sulfated glucosamineglycans serve ubiquitous roles in cell adhesion and receptor signaling. Heparin, a highly sulfated polymer of uronic acids and glucosamine, binds strongly to the integrin receptor alphaXbeta2 (p150,95, CD11c/CD18). Here, we analyze the structural motifs within heparin that constitute high affinity binding sites for the I domain of integrin alphaXbeta2. Heparin oligomers with chain lengths of 10 saccharide residues or higher provide strong inhibition of the binding by the alphaX I domain to the complement fragment iC3b. By contrast, smaller oligomers or the synthetic heparinoid fondaparinux were not able to block the binding. Semipurified heparin oligomers with 12 saccharide residues identified the fully sulfated species as the most potent antagonist of iC3b, with a 1.3 microM affinity for the alphaX I domain. In studies of direct binding by the alphaX I domain to immobilized heparin, we found that the interaction is conformationally regulated and requires Mg2+. Furthermore, the fully sulfated heparin fragment induced conformational change in the ectodomain of the alphaXbeta2 receptor, also demonstrating allosteric linkage between heparin binding and integrin conformation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142650PMC
http://dx.doi.org/10.1074/jbc.M706114200DOI Listing

Publication Analysis

Top Keywords

alphax domain
12
binding integrin
8
integrin alphaxbeta2
8
heparin
8
heparin oligomers
8
saccharide residues
8
binding alphax
8
fully sulfated
8
binding
6
alphaxbeta2
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!